The locomotor effects of MK801 in the nucleus accumbens of developing and adult rats

European Journal of Pharmacology

Volumn 368, Issue 2-3, 1999, Pages 125-135

  Frantz, Kyle ^a   Van Hartesveldt, Carol ^a  

^a Univ of Florida PO Box 112250 ^*  (United States)

Author keywords

Dizocilpine; Dopamine; Glutamate; Novel environment; Ontogeny

Indexed keywords

DIZOCILPINE; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; INTRACEREBRAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MATURATION; NONHUMAN; NUCLEUS ACCUMBENS; ONTOGENY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; INJECTIONS, INTRAVENTRICULAR; LOCOMOTION; MALE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0032976762     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00009-6     Document Type: Article

References (85)

1. Alexander G.E., Goldman P.S. Functional development of the dorsolateral prefrontal cortex: an analysis utilizing reversible cryogenic depression. Brain Res. 143:1978;233-249.
2. Al-Khatib I., Karadag H.C., Ulogol A. The behavioral effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats. Pharmacol. Biochem. Behav. 52:1995;723-730.
3. Angevine, J.B., Jr., 1975. Development of the hippocampal region. In: Isaacson, R.L., Pribram, K.H. (Eds.), The Hippocampus: Vol. 1. Structure and Development. Plenum, New York, NY, pp. 61-94.
4. Arnt J. Differential behavioural effects of dopamine agonists in developing rats: a study of 3-PPP enantiomers. Eur. J. Pharmacol. 91:1983;273-278.
5. Barrett B.A., Caza P., Spear N.E., Spear L.P. Wall climbing, odors from the home nest and catecholaminergic activity in rat pups. Physiol. Behav. 29:1982;501-507.
6. Benes F.M. Myelination of cortical-hippocampal relays during late adolescence. Schizophr. Bull. 15:1989;585-593.
7. Blanchard D.C., Blanchard R.J., Carobrez A.D.P., Veniegas R., Rodgers R.J., Shepherd J.K. MK-801 produces a reduction in anxiety-related antipredator defensiveness in male and female rats and a gender-dependent increase in locomotor behavior. Psychopharmacology. 108:1992;352-362.
8. Boldry R.C., Uretsky N.J. The importance of dopaminergic neurotransmission in the hypermotility response produced by the administration of N-methyl-D-aspartic acid into the nucleus accumbens. Neuropharmacology. 27:1988;569-577.
9. Boldry R.C., Willins D.L., Wallace L.J., Uretsky N.J. The role of endogenous dopamine in the hypermotility response to intra-accumbens AMPA. Brain Res. 559:1991;100-108.
10. Bradberry C.W., Gruen R.J., Berridge C.W., Roth R.H. Individual differences in behavioral measures: correlations with nucleus accumbens dopamine measured by microdialysis. Pharmacol. Biochem. Behav. 39:1991;877-882.
11. Burns L.H., Everitt B.J., Kelley A.E., Robbins T.W. Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement. Psychopharmacology. 115:1994;516-528.
12. Campbell B.A., Lytle L.D., Fibiger H.C. Ontogeny of adrenergic arousal and cholinergic inhibitory mechanisms in the rat. Science. 166:1969;635-637.
13. Campochiaro P., Coyle J.T. Ontogenetic development of kainate neurotoxicity: correlates with glutamatergic innervation. Proc. Natl. Acad. Sci. 75:1978;2025-2029.
14. Carlezon W.A., Wise R.A. Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J. Neurosci. 16:1996;3112-3122.
15. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
16. Carlsson M., Svensson A. Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems. Pharmacol. Biochem. Behav. 36:1990;45-50.
17. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci. 61(2):1997;75-94.
18. Criswell H.E., Johnson K.B., Mueller R.A., Breese G.R. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. J. Pharmacol. Exp. Ther. 265:1993;1001-1010.
19. Dall-'Olio R., Rimondini R., Gandolfi O. Effect of NMDA receptor antagonists on D1, D2 and D1/D2 mediated behaviors in intact rats. Psychopharmacology. 123:1996;187-190.
20. Danneman P.J., Mandrell T.D. Evaluation of five agents/methods for anesthesia of neonatal rats. Lab. Anim. Sci. 47(4):1997;386-395.
21. Donzanti B.A., Uretsky N.J. Effects of excitatory amino acids on locomotor activity after bilateral microinjection into the rat nucleus accumbens: possible dependence on dopaminergic mechanisms. Neuropharmacology. 22:1983;971-981.
22. Doran A.R., Boronow J., Weinberger D.R., Wolkowitz O.M., Breier A., Pickar D. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology. 1:1987;25-32.
23. Ferré S., Gimenez-Llort L., Artigas F., Martinez E. Motor activation in short- and long-term reserpinized mice: role of N-methyl-D-aspartate, dopamine D1 and dopamine D2 receptors. Eur. J. Pharmacol. 255:1994;203-213.
24. Fleischmann A., Vincent P.A., Etgen A.M. Effects of non-competitive NMDA receptor antagonists on reproductive and motor behaviors in female rats. Brain Res. 568:1991;138-146.
25. Flores G., Barbeau D., Quirion R., Srivastava L. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J. Neurosci. 16(6):1996;2020-2026.
26. Ford L.M., Norman A.B., Sanberg P.R. The topography of MK-801-induced locomotor patterns in rats. Physiol. Behav. 46:1989;755-758.
27. Frantz K., Van Hartesveldt C. Locomotor effects of quinpirole in the nucleus accumbens of developing rat pups. Soc. Neuroci. Abstr. 21:1995;280.
28. Frantz K., Babcock D., Van Hartesveldt C. The locomotor effects of a putative dopamine D3 receptor agonist in developing rats. Eur. J. Pharmacol. 302:1996;1-6.
29. Green R.J., Stanton M.E. Differential ontogeny of working memory and reference memory in the rat. Behav. Neurosci. 103(1):1989;98-105.
30. Greenamyre T., Penney J.F., Young A.B., Hudson C., Silverstein F.S., Johnston M.V. Evidence for transient perinatal glutamatergic innervation of globus pallidus. J. Neurosci. 7:1987;1022-1030.
31. Haggerty G.C., Brown G. Neurobehavioral profile of subcutaneously administered MK-801 in the rat. Neurotoxicology. 17(3-4):1996;913-922.
32. Halberstadt A.L. The phencyclidine-glutamate model of schizophrenia. Clin. Neuropharmacol. 18:1995;237-249.
33. Hamilton M.H., deBelleroche J.S., Gardiner I.M., Herberg L.J. Stimulatory effect of N-methyl-D-aspartate on locomotor activity and transmitter release from rat nucleus accumbens. Pharmacol. Biochem. Behav. 25:1986;943-948.
34. Hargreaves E.L., Cain D.P. Hyperactivity, hyper-reactivity, and sensorimotor deficits induced by low doses of the N-methyl-D-aspartate non-competitive channel blocker MK801. Dev. Brain Res. 47(1):1992;23-33.
35. Heimer, L., Alheid, G.F., Zahm, D.S., 1993. Basal forebrain organization: an anatomical framework for motor aspects of drive and motivation. In: Barnes, C.D., Kalivas, P.W. (Eds.), Limbic Motor Circuits and Neuropsychiatry. CRC Press, Boca Raton, FL, pp. 1-44.
36. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. Gen. Sect. 89:1992;1-10.
37. Hönack D., Löscher W. Sex differences in NMDA receptor mediated responses in rats. Brain Res. 620:1993;167-170.
38. Hooks et al., 1992.
39. Horger B.A., Roth R.H. The role of mesoprefrontal dopamine neurons in stress. Crit. Rev. Neurobiol. 10(3-4):1995;395-418.
40. Insel et al., 1990.
41. Kelley A.E., Throne L.C. NMDA receptors mediate the behavioral effects of amphetamine infused into the nucleus accumbens. Brain Res. Bull. 29:1992;247-254.
42. LeMoal M., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev. 71(1):1991;155-234.
43. Maldonado-Irizarry C.S., Kelley A.E. Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacology. 116:1994;65-72.
44. Mogenson G.J., Nielsen M. Neuropharmacological evidence to suggest that the nucleus accumbens and subpallidal region contribute to exploratory locomotion. Behav. Neural Biol. 42:1984;52-60.
45. Mogenson G.J., Wu M. Effects of administration of dopamine D2 agonist quinpirole on exploratory locomotion. Brain Res. 551:1991;216-219.
46. Mogenson G.J., Wu M. Quinpirole to the accumbens reduced exploratory and amphetamine-elicited locomotion. Brain Res. Bull. 27:1991;743-746.
47. Mogenson, G.J., Brudzynski, S.M., Wu, M., Yang, C.R., Yim, C.C.Y., 1993. From motivation to action: a review of dopaminergic regulation of limbic-nucleus accumbens-ventral pallidum-pedunculopontine nucleus circuitries involved in limbic-motor integration. In: Kalivas, P.W., Barnes, C.D., (Eds.), Limbic Motor Circuits and Neuropsychiatry. CRC Press, Boca Raton, FL, pp. 193-236.
48. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: comparison to hippocampus and basal ganglia. J. Neurochem. 60:1993;1650-1657.
49. Moghaddam B. Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;859-870.
50. Ögren S.-O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology. 11:1994;167-177.
51. O'Keefe, J., Nadel, L., 1978. The Hippocampus as a Cognitive Map. Clarendon Press, Oxford.
52. Olney J.W., Farber N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 13:1995;335-345.
53. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
54. Ouagazzal A.-M., Nieoullon A., Amalric M. Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum. Eur. J. Pharmacol. 251:1994;229-236.
55. Pulvirenti L., Swerdlow N.R., Koob G.F. Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol. Biochem. Behav. 40:1991;841-845.
56. Raffa R.B., Ortegon M.E., Robisch D.M., Martin G.E. In vivo demonstration of the enhancement of MK-801 by L-glutamate. Life Sci. 44:1989;1593-1599.
57. Rajachandran L., Goodwin G.A., Spear L.P. Psychopharmacological effects of MK-801 in infant and preweanling rat pups. Pharmacol. Biochem. Behav. 40:1991;291-295.
58. Randall, Campbell Ontogeny of behavioral arousal in rats: effect of maternal and sibling presence. J. Comp. Physiol. Psychol. 90(5):1976;453-459.
59. Salamone J.D. The involvement of nucleus accumbens dopamine in appetitive and aversive motivation. Behav. Brain Res. 61:1994;117-133.
60. Salamone J.D. The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine. J. Neurosci. Meth. 64:1996;137-149.
61. Scalzo F.M., Burge L.J. The role of NMDA and sigma systems in the behavioral effects of phencyclidine in preweanling rats. Neurotoxicology. 15:1994;191-200.
62. Shalaby I.A., Spear L.P. Psychopharmacological effects of low and high doses of apomorphine during ontogeny. Eur. J. Pharmacol. 67:1980;451-459.
63. Shalaby et al., 1981.
64. Spear L.P., Brake S.C. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev. Psychobiol. 16:1983;83-109.
65. Starr M.S., Starr B.S. Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur. J. Pharmacol. 250:1993;239-246.
66. Starr M.S., Starr B.S. Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice. Psychopharmacology. 114:1994;469-476.
67. Subramaniam S., McGonigle P. Regional profile of developmental changes in the sensitivity of the N-methyl-D-aspartate receptor to polyamines. J. Neurochem. 62:1994;1408-1415.
68. Svensson A., Carlsson M. Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation. Neuropharmacology. 31:1992;513-518.
69. Svensson A., Carlsson A., Carlsson M. Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J. Neural Transm. Gen. Sect. 90:1992;199-217.
70. Svensson A., Carlsson M., Carlsson A. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: evidence for a dual glutamatergic function with respect to psychomotor control. J. Neural Transm. Gen. Sect. 88:1992;235-240.
71. Svensson A., Carlsson M., Carlsson A. Glutamatergic neurons projecting to the nucleus accumbens can affect motor functions in opposite directions depending on the dopaminergic tone. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;1203-1218.
72. Van Hartesveldt C. Temporal and environmental effects on quinpirole-induced biphasic locomotion in rats. Pharmacol. Biochem. Behav. 58(4):1997;955-960.
73. Van Hartesveldt C., Cottrell G.A., Potter T., Meyer M. Effects of intracerebral quinpirole on locomotion in rats. Eur. J. Pharmacol. 214:1992;27-32.
74. Van Hartesveldt C., Meyer M.E., Potter T.J. Ontogeny of biphasic locomotor effects of quinpirole. Pharmacol. Biochem. Behav. 48:1994;781-786.
75. Villablanca J.R., Marcus R.J., Olmstead C.E. Effects of caudate nuclei or frontal cortical ablations in cats: I. Neurology and gross behavior. Exp. Neurol. 52:1976;389-420.
76. Wachtel H., Turski L. Glutamate: a new target in schizophrenia? T.i.P.S. 11:1990;219-220.
77. Walker E.F. Developmentally moderated expressions of the neuropathology underlying schizophrenia. Schizophr. Bull. 20(3):1994;453-480.
78. Wan R.Q., Giovanni A., Kafka S.H., Corbett R. Neonatal hippocampal lesions induced hyperresponsiveness to amphetamine: behavioral and in vivo microdialysis studies. Behav. Brain Res. 78(2):1996;211-223.
79. Weinberger D.R. Schizophrenia and the frontal lobe. T.i.N.S. 11:1988;367-370.
80. Weinberger D.R., Berman K.F., Illowsky B.P. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Arch. Gen. Psychiatry. 45:1988;609-645.
81. Willins D.L., Narayanan S., Wallace L.J., Uretsky N.J. The role of dopamine and AMPA/kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol. Biochem. Behav. 46:1993;881-887.
82. Willner P., Muscat R., Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16:1992;525-534.
83. Wixson S.K., White W.J., Hughes H.C. Jr., Lang C.M., Marshall W.K. A comparison of pentobarbital, fentanyl-droperidol, ketamine-xylazine and ketamine-diazepam anesthesia in adult male rats. Lab. Anim. Sci. 37(6):1987;726-730.
84. Wu M., Brudzynski S.M., Mogenson G.J. Differential effects of quinpirole in the nucleus accumbens depending on the initial level of locomotor activity. Brain Res. Bull. 32:1993;395-398.
85. Wu M., Brudzynski S.M., Mogenson G.J. Functional interaction of dopamine and glutamate in the nucleus accumbens in the regulation of locomotion. Can. J. Physiol. Pharmacol. 71:1993;407-413.